Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 1
1999 3
2001 1
2002 4
2003 4
2004 7
2005 4
2006 3
2007 3
2008 5
2009 2
2012 1
2013 4
2014 2
2015 4
2016 6
2017 3
2018 5
2019 3
2020 4
2021 5
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

65 results
Results by year
Filters applied: . Clear all
Page 1
Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.
Duinkerken CW, de Weger VA, Dreschler WA, van der Molen L, Pluim D, Rosing H, Nuijen B, Hauptmann M, Beijnen JH, Balm AJM, de Boer JP, Burgers JA, Marchetti S, Schellens JHM, Zuur CL. Duinkerken CW, et al. Among authors: pluim d. Otol Neurotol. 2021 Jun 1;42(5):678-685. doi: 10.1097/MAO.0000000000003069. Otol Neurotol. 2021. PMID: 33710154 Clinical Trial.
Phase I pharmacological study of continuous chronomodulated capecitabine treatment.
Roosendaal J, Jacobs BAW, Pluim D, Rosing H, de Vries N, van Werkhoven E, Nuijen B, Beijnen JH, Huitema ADR, Schellens JHM, Marchetti S. Roosendaal J, et al. Among authors: pluim d. Pharm Res. 2020 May 7;37(5):89. doi: 10.1007/s11095-020-02828-6. Pharm Res. 2020. PMID: 32382808 Free PMC article. Clinical Trial.
A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
Geenen JJJ, Dackus GMHE, Schouten PC, Pluim D, Marchetti S, Sonke GS, Jóźwiak K, Huitema ADR, Beijnen JH, Schellens JHM, Linn SC. Geenen JJJ, et al. Among authors: pluim d. Int J Cancer. 2021 Jun 15;148(12):3041-3050. doi: 10.1002/ijc.33498. Epub 2021 Feb 27. Int J Cancer. 2021. PMID: 33539540 Free PMC article. Clinical Trial.
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer.
de Haan R, van den Heuvel MM, van Diessen J, Peulen HMU, van Werkhoven E, de Langen AJ, Lalezari F, Pluim D, Verwijs-Janssen M, Vens C, Schellens JHM, Steeghs N, Verheij M, van Triest B. de Haan R, et al. Among authors: pluim d. Clin Cancer Res. 2021 Mar 1;27(5):1256-1266. doi: 10.1158/1078-0432.CCR-20-2551. Epub 2020 Dec 1. Clin Cancer Res. 2021. PMID: 33262140 Clinical Trial.
Therapeutic Exposure and Successful Response to Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer Despite Significant Renal Loss Due to Paraneoplastic Nephrotic Syndrome.
Jansen AME, Sriram JD, Pluim D, Maas RJH, van Groningen H, Piet B, Ter Heine R. Jansen AME, et al. Among authors: pluim d. Clin Lung Cancer. 2021 Mar;22(2):e220-e223. doi: 10.1016/j.cllc.2020.09.021. Epub 2020 Oct 14. Clin Lung Cancer. 2021. PMID: 33189593 Free article. No abstract available.
Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers.
Siddiqui A, Gollavilli PN, Schwab A, Vazakidou ME, Ersan PG, Ramakrishnan M, Pluim D, Coggins S, Saatci O, Annaratone L, Hm Schellens J, Kim B, Asangani IA, Rasheed SAK, Marchiò C, Sahin O, Ceppi P. Siddiqui A, et al. Among authors: pluim d. Cell Death Differ. 2019 Nov;26(11):2223-2236. doi: 10.1038/s41418-019-0289-6. Epub 2019 Feb 8. Cell Death Differ. 2019. PMID: 30737477 Free PMC article.
65 results